26 April 2023 08:30ZICCUM AB (publ) releases Interim report Q1 2023
To read the digital Report click here: https://reports-en.ziccum.com/interim-report-q1-2023/ SIGNIFICANT EVENTS Q1 2023 (JAN-MARCH) On January 18, Ziccum announced that the company on 24 - 26 January would attend the mRNA-based Therapeutics Summit in...
24 April 2023 15:25KALLELSE TILL ÅRSSTÄMMA I ZICCUM AB (PUBL)
20 March 2023 08:30Ziccum reports positive results from drying of active mRNA and promising mRNA activity after powder reconstitution
Ziccum today announces an update of the latest stage of its ongoing in-house mRNA/LNP project, last reported on October 24, 2022. In the previous stage, an mRNA-like molecule in LNP formulation was successfully nebulized and dried. The current stage has...
17 March 2023 08:40Ziccum to attend BIO-Europe Spring in Basel
Ziccum CEO Ann Gidner and Chairman Fredrik Sjövall will attend the BIO-Europe Spring 2023 Conference in Basel, Switzerland March 20 – 22. The event attracts pharma and biopharma corporations from across the globe. The latest updates from Ziccum...
10 March 2023 08:30Ziccum AB joins innovative financial platform for Investor Relations management and European outreach
Ziccum AB (publ) (‘Ziccum’) has entered into a partnership with the FinTech platform eucaps.com, aiming to offer existing shareholders a new forum for news and dialogue whilst also increasing visibility to new investors beyond Sweden. As of...
17 February 2023 11:00ZICCUM AB (publ) releases Annual Report 2022
Ziccum’s Annual Report for 2022 is available from today on the company’s website, www.ziccum.com To read the digital Report in full (in Swedish) click here: https://reports.ziccum.com/arsredovisning-2022/ziccum-2022/ Ziccum’s Annual...
27 January 2023 08:30ZICCUM AB (publ) Year-end report Q4 2022
YEAR-END REPORT Q4 2022: 1 JANUARY – 31 DECEMBER 2022 To read the digital Report, please click here: https://reports-en.ziccum.com/year-end-report-q4-2022/start/ Significant events in Q4 (October - December) On October 24, Ziccum announced proof...
23 January 2023 15:07Ziccum submits Expression of Interest for CEPI funding
Ziccum AB (publ) (‘Ziccum’) has now submitted its Expression of Interest application for CEPI’s Call for Proposals for funding of innovations that improve vaccine thermostability. The Coalition for Epidemic Preparedness (CEPI), in 2022...
18 January 2023 12:30Ziccum CEO to present at international mRNA Summit in Berlin
Lund, Jan 18, 2023 —Ziccum AB CEO Ann Gidner will present LaminarPace, the company’s unique mass transfer drying methodology, at the mRNA-based Therapeutics Summit in Berlin 24 – 26 January. It is the leading European event for mRNA...
16 December 2022 20:00Ziccum awarded 10 MSEK Eurostars funding for 3D-modeling and Digital twin project
Ziccum AB has been awarded non-dilutive funding of 10 MSEK by Eurostars for a joint application with the Institute of Computational Physics (ICP) at the School of Engineering at Zurich University of Applied Sciences (ZHAW). The project (application #...
14 December 2022 16:16Ziccum launches new, expanded website
Lund, Nov 14, 2022 —Ziccum AB (publ) (‘Ziccum’) has launched a new website, developed in partnership with the Chords Agency in Malmö. With a new brand platform, the expanded site aims to strengthen the company’s dialogue with...
8 December 2022 09:25Ziccum signs agreement with Zurich University of Applied Sciences on advanced 3D-modeling project
Ziccum AB has signed an agreement contracting the ICP Institute of Computational Physics at the Zurich University of Applied Sciences’ School of Engineering (ZHAW) for the next phase of the project developing 3D modelling of LaminarPace - Ziccum’s...
28 October 2022 16:50Ziccums Q3-resultat: VD-uppdatering på svenska
Ziccum har haft ett mycket produktivt kvartal, med avsevärda framsteg inom de tre fokusområdena: Partnering, Teknologiutveckling och Förstudien för mRA/LNP-plattformen. Ann Gidner, Ziccums nya VD som tillträdde i maj månad...
27 October 2022 08:30ZICCUM AB (publ) Interim report Q3 2022
INTERIM REPORT Q3 2022: 1 JANUARY – 30 SEPTEMBER 2022. To read the digital Report, please click here: https://reports-en.ziccum.com/interim-report-q3-2022/start/ Significant events during Q3 (July-September) On July 19, Ziccum published the selected...
24 October 2022 08:20Ziccum generates proof of successful drying of lipid nanoparticles in mRNA project
ZICCUM AB (publ) has generated proof of successful nebulization and drying of vaccine lipid nanoparticles (LNP) in its in-house mRNA project. This was carried out using LaminarPaceTM, the company’s ambient drying technology. LNP is the preferred...
27 September 2022 08:30Ziccum reopens application for CEPI funding on thermostable vaccines with new partner
Ziccum AB (publ) (‘Ziccum’) today announces that is has reopened its application process for CEPI’s Call for Proposals (CfP) from companies developing innovative technologies to improve vaccine thermostability. Ziccum will submit an...
23 September 2022 15:12Ziccum receives results from evaluation study with leading Pharmaceutical Corporation
Ziccum AB (publ) (‘Ziccum’) has today received readout results from the latest stage of an evaluation agreement study carried out with a leading pharmaceutical corporation (previously communicated on June 3, 2022) analyzing LaminarPace’s...
14 September 2022 15:30Ziccum and Zurich University of Applied Sciences submit joint application for Eurostars funding
Following their agreed collaboration, Ziccum AB and the team from the ICP Institute of Computational Physics at the Zurich University of Applied Sciences’s School of Engineering (ZHAW) have now submitted an application to the Eurostars funding body...
1 September 2022 08:35Ziccum on the move: company to attend major industry events across Europe in 2022
Ziccum AB will be intensifying its partnering and networking dialogues at a series of leading pharma industry events throughout Europe this year. CEO Ann Gidner: “As we strengthen our connections with colleagues throughout the industry, we remain...
23 August 2022 08:30ZICCUM AB (publ) Interim report Q2 2022
INTERIM REPORT Q2 2022: 1 JANUARY – 30 JUNE 2022. To read the digital Report click here: https://reports-en.ziccum.com/interim-report-q2-2022/ Significant events during Q2 (April-June) Significant events during Q1 (Jan-March) With a new CEO, the...